### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

\_\_\_\_

#### BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS, INC. Petitioner,

V.

SENJU PHARMACEUTICAL CO., LTD. Patent Owner.

U.S. Patent No. 8,877,168 to Higashiyama
Issue Date: November 4, 2014
Title: Aqueous Liquid Preparations and Light-Stabilized Aqueous Liquid
Preparations

\_\_\_\_\_

Inter Partes Review No.: IPR2016-01163

**Petitioner's Exhibit List** 

Mail Stop "PATENT BOARD"
Patent Trial and Appeal Board
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450




# **Petitioner's Exhibit List**

Petitioner	- · ·
Exhibit #	Description
1001	Higashiyama, U.S. Patent No. 8,784,789, "Aqueous Liquid
	Preparations and Light-Stabilized Aqueous Liquid Preparations"
1000	("the '789 patent")
1002	Higashiyama, U.S. Patent No. 8,877,168 "Aqueous Liquid
	Preparations and Light-Stabilized Aqueous Liquid Preparations"
1003	("the '168 patent")  Declaration of Dr. Mansoor M. Amiji
1003	Yanni et al., U.S. Patent No. 6,174,914 "Method of Inhibiting
1004	Cytokine Release from Human Ocular Cells" ("Yanni")
1005	Remington: The Science and Practice of Pharmacy 20th Ed.
	("Hecht")
1006	Lloyd V. Allen Jr. et al. "Compounding Ophthalmic Preparations,"
	International Journal of Pharmaceutical Compounding 2(3) (1998)
100=	("Allen")
1007	Tetsuya Araki et al., "Photochemical Behavior of Sitafloxacin,
	Fluoroquinolone Antibiotic, in an Aqueous Solution," Chemical and Pharmaceutical Bulletin 50(2) 229-234 (2002) ("Araki I")
1008	Press Release "Tanabe Seiyaku Granted Rights for Bepotastine
1000	Besilate for Ophtalmic [sic] Use to Senju Seiyaku (Japan)"
	("Tanabe")
1009	Masanori Araki et al., PCT International Patent Publication No.
	WO 01/080858 "Stable Liquid Preparation" ("Araki II")
1010	R.J. Davies et al., Antihistamines: topical vs. oral administration,
1011	Clinical and Experimental Allergy 26(3):11-17 (1996) ("Davies")
1011	"Stability Testing: Photostability Testing of New Drug Substances and Products," ICH Harmonized Tripartite Guideline (1996) ("ICH
	Guideline")
1012	Dolores Kostecka et al., "Formulation of a Stable Parenteral
-	Product; Clonidine Hydrochloride Injection," PDA Journal of
	Pharmaceutical Science & Technology 56(6):320-325 (1998)
	("Kostecka")
1013	Gerold L. Mosher et al., "Photoreactivity of LY277359 Maleate, a
	5- Hydroxytryptamine3 (5-HT3) Receptor Antagonist, in
	Solution," Pharmaceutical Research 8(10):1215-1222 (1991)
1014	("Mosher") Reserved
1014	10001 VOG



1015	Press Release "Regarding Extended Indication for Selective
1016	Histamine H1 Receptor Antagonist/Anti-Allergic Agent Talion®
	Tablets 5 and Talion® Tablets 10 in Treating Pruritus/Itching
	Accompanying Urticaria and Other Skin Diseases" ("Talion Press
	Release")
1016	Remington's Pharmaceutical Sciences 16th Ed., pp. 1403-1419
	(1980) ("Remington").
1017	Jun-ichiro Kita et al., European Patent Publication No. EP 0 949
	260 "Acid-Addition Salts of Optically Active Piperidine
	Compound and Process for Producing the Same" ("Kita")
1018	CV of Dr. Mansoor M. Amiji
1019	Declaration of Higashiyama Under 37 CFR § 1.132 of Nov. 6, 2007
1020	Supplemental Amendment of Nov. 13, 2007
1021	Final Office Action of Feb. 8, 2008
1022	Declaration of Higashiyama of Dec. 22, 2008
1023	Amendment of Jan. 5, 2009
1024	Office Action of May 8, 2009
1025	Office Action of April 9, 2010
1026	Final Office Action of Dec. 20, 2010
1027	Declaration of Higashiyama of Sept., 11, 2012
1028	Supplemental Amendment of Sept. 14, 2012
1029	Office Action of Aug. 30, 2013
1030	Amendment of May 30, 2014
1031	Notice of Allowance of June 12, 2014
1032	Amendment of April 24, 2012
1033	Final Office Action of Apr. 30, 2014
1034	Examiner Interview Summary of August 11, 2018 in '678
	application



### **CERTIFICATION OF SERVICE ON PATENT OWNER**

Pursuant to 37 C.F.R. §§ 42.6(e), 42.8(b)(4) and 42.105, the undersigned certifies that on the 8th day of June 2016, a complete copy of the foregoing Petition for *Inter Partes* Review of U.S. Patent No. 8,877,168, Power of Attorney, Exhibit List, and all supporting exhibits were served via UPS® to the Patent Owner by serving the correspondence address of record for the '168 patent:

WENDEROTH, LIND & PONACK, L.L.P. 1030 15th Street, N.W., Suite 400 East Washington DC 20005-1503

Courtesy copies of the foregoing were also served via UPS® on counsel of record for the Patent Owner in *Bausch & Lomb Inc. et al. v. Micro Labs Ltd. et al.*, No. 15-cv-03113-NLH-JS (D.N.J.) as follows:

Melissa A. Chuderewicz PEPPER HAMILTON 301 Carnegie Center Suite 400 Princeton, New Jersey 08543-5276 T: (609) 951-4118 F: (609) 452-1147

chuderem@pepperlaw.com

Bryan C. Diner
Justin J. Hasford
FINNEGAN, HENDERSON, FARABOW, GARRETT &
DUNNER, LLP
901 New York Avenue, NW
Washington, DC 20001-4413

T: (202) 408-4000 F: (202) 408-4400



## bryan.diner@finnegan.com justin.hasford@finnegan.com

Respectfully submitted,

Alston & Bird LLP

By: /Jitendra Malik/

Jitendra Malik, Ph.D.
Reg. No. 55823
Alston & Bird LLP
4721 Emperor Blvd., Suite 400
Durham, NC 27703-8580
jitty.malik@alston.com

Lance Soderstrom
Reg. No. 65405
Alston & Bird LLP
90 Park Avenue, 15th Floor
New York, New York 10016-1387
lance.soderstrom@alston.com

H. James Abe Reg. No. 61182 Alston & Bird LLP 333 South Hope Street, 16th Floor Los Angeles, CA 90071 james.abe@alston.com

Joseph M. Janusz Reg. No. 70396 Alston & Bird LLP 101 S. Tryon Street, Suite 4000 Charlotte, NC 28205 joe.janusz@alston.com

Attorneys for Petitioner Mylan Pharmaceuticals, Inc.

